Journal ArticleDOI
Castration-Resistant Prostate Cancer: AUA Guideline
Michael S. Cookson,Bruce J. Roth,Philipp Dahm,Christine Engstrom,Stephen J. Freedland,Maha Hussain,Daniel W. Lin,William T. Lowrance,Mohammad Hassan Murad,William Oh,David F. Penson,Adam S. Kibel +11 more
TLDR
This guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data.About:
This article is published in The Journal of Urology.The article was published on 2013-08-01. It has received 273 citations till now. The article focuses on the topics: Guideline.read more
Citations
More filters
Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy
TL;DR: Abiraterone inhibits CYP-17, a crucial enzyme in androgen biosynthesis in the testes, adrenal glands, and in prostate cancer cells as discussed by the authors, and showed a strong trend toward improved survival.
Journal ArticleDOI
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas D. James,Melissa R. Spears,Noel W. Clarke,David P. Dearnaley,Johann S. de Bono,Joanna Gale,J. Hetherington,Peter Hoskin,Robert Jones,Robert W. Laing,Jason F. Lester,Duncan B. McLaren,Chris Parker,Mahesh K. B. Parmar,A.W.S. Ritchie,J. Martin Russell,Räto T. Strebel,George N. Thalmann,Malcolm David Mason,Matthew R. Sydes +19 more
TL;DR: Survival remains disappointing in men presenting with M1 disease who are started on only long-term androgen deprivation therapy (ADT), despite active treatments being available at first failure of ADT.
Journal ArticleDOI
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin,Oliver Sartor,Joe M. O'Sullivan,Dag Clement Johannessen,Svein Inge Helle,John P Logue,David Bottomley,Sten Nilsson,Nicholas J. Vogelzang,Fang Fang,Mona Wahba,Anne-Kirsti Aksnes,Chris Parker +12 more
TL;DR: Radium-223 is effective and well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases, irrespective of previous docetaxel use and the benefit of radium-223 compared with placebo was seen in both docetAXel subgroups for most main secondary efficacy endpoints.
Journal ArticleDOI
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
TL;DR: Multiple mechanisms of resistance to ADT and currently approved CRPC treatments will help guide future research into targeted therapies, and some of the mechanisms by which these agents fail are unique, many share similarities to the mechanisms contributing to CRPC progression.
Journal ArticleDOI
METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer
Anwar R. Padhani,Frédéric Lecouvet,Nina Tunariu,Dow-Mu Koh,Frederik De Keyzer,David J. Collins,Evis Sala,Heinz Peter Schlemmer,Giuseppe Petralia,H. Alberto Vargas,Stefano Fanti,H. Bertrand Tombal,Johann S. de Bono +12 more
TL;DR: The METastasis Reporting and Data System for Prostate Cancer represents the consensus recommendations on the performance, quality standards, and reporting of whole-body magnetic resonance imaging, for use in all oncologic manifestations of advanced prostate cancer.
References
More filters
Journal ArticleDOI
Cancer statistics, 2012
TL;DR: The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 1,024,400 deaths from cancer, which can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket.
Journal ArticleDOI
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken,Richard H. Creech,Douglass C. Tormey,John Horton,Thomas E. Davis,Eleanor T. McFadden,Paul P. Carbone +6 more
TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI
Grading quality of evidence and strength of recommendations.
David C. Atkins,Dana Best,Peter A. Briss,Martin P Eccles,Yngve Falck-Ytter,Signe Flottorp,Gordon H. Guyatt,Robin Harbour,Margaret C Haugh,David Henry,Suzanne Hill,Roman Jaeschke,Gillian Leng,Alessandro Liberati,Nicola Magrini,James Mason,Philippa Middleton,Jacek Mrukowicz,Dianne L. O'Connell,Andrew D Oxman,Bob Phillips,Holger J. Schünemann,Tessa Tan-Torres Edejer,H. Varonen,Gunn Elisabeth Vist,John W Williams,Stephanie Zaza +26 more
TL;DR: A system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts is developed, and a summary of the approach from the perspective of a guideline user is presented.
Journal ArticleDOI
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Journal ArticleDOI
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem,Mark Helfand,Mark Helfand,Holger J. Schünemann,Andrew D Oxman,Regina Kunz,Jan Brozek,Gunn Elisabeth Vist,Yngve Falck-Ytter,Joerg J Meerpohl,Susan L Norris,Gordon H. Guyatt +11 more
TL;DR: The approach of GRADE to rating quality of evidence specifies four categories-high, moderate, low, and very low-that are applied to a body of evidence, not to individual studies.
Related Papers (5)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more